Your browser doesn't support javascript.
loading
PARP inhibitors in prostate cancers, is it time for combinations?
Teyssonneau, Diego; Dariane, Charles; Barret, Eric; Beauval, Jean-Baptiste; Brureau, Laurent; Fiard, Gaëlle; Fromont, Gaëlle; Créhange, Gilles; Gauthé, Mathieu; Ruffion, Alain; Renard-Penna, Raphaële; Mathieu, Romain; Sargos, Paul; Rouprêt, Morgan; Ploussard, Guillaume; Roubaud, Guilhem.
Afiliación
  • Teyssonneau D; Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux 33000, France.
  • Dariane C; Department of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris University, U1151 Inserm-INEM, Necker, Paris, France.
  • Barret E; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Beauval JB; Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.
  • Brureau L; IUCT-O, Toulouse, France.
  • Fiard G; Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Pointe-à-Pitre, France.
  • Fromont G; Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.
  • Créhange G; Department of Pathology, CHRU Tours, Tours, France.
  • Gauthé M; Department of Radiation Oncology Curie Institute, Paris, France.
  • Ruffion A; Department of Nuclear Medicine, Scintep, Grenoble, France.
  • Renard-Penna R; Service d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon.
  • Mathieu R; Equipe 2, Centre d'Innovation en Cancérologie de Lyon (EA 3738 CICLY), Faculté de Médecine Lyon Sud, Université Lyon 1, Lyon, France.
  • Sargos P; AP-HP, Radiology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.
  • Rouprêt M; Department of Urology, University of Rennes, Rennes, France.
  • Ploussard G; University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), Rennes, France.
  • Roubaud G; Department of Radiotherapy, Institut Bergonié, Bordeaux, Aquitaine, France.
Ther Adv Med Oncol ; 16: 17588359241242959, 2024.
Article en En | MEDLINE | ID: mdl-38827177
ABSTRACT
Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido